CS Capital
VC Fund
Shanghai, China
CS Capital is an investment firm that offers investment management service.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries CS Capital invests in
Stages CS Capital invests in
Countries CS Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Investment Focus
Industry
- Biotechnology 11 (52%)
- Medical 8 (38%)
- Health Care 8 (38%)
- Biopharma 3 (14%)
- Pharmaceutical 3 (14%)
Stage
- Series B 9 (43%)
- Series A 5 (24%)
- Seed 3 (14%)
- Series C 2 (10%)
- Series D 1 (5%)
Country
- China 18 (86%)
- United States 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Min Lou
CEO & Co-founder
|
CEO & Co-founder | Total investments: 0 | Find email | |
|
Yinghui Wu
Partner
|
Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Junhemeng Biopharmaceutical
|
Junhemeng is a research and development company of recombinant protein drugs. | $29.5M / Series C / Jun 08, 2026 | |
|
Tianyikang Biotechnology
|
Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products. | Seed / Feb 09, 2026 | |
|
Changfeng Bio
|
Changfeng Bio is the developer of biomedical material technologies, focused on addressing clinical challenges across medical disciplines. | Seed / Sep 12, 2025 | |
Lingmo Medical
|
Lingmo Medical is a company that provides department-level flexible endoscopic solutions.It is advancing the development of flexible endoscopy and providing higher-quality endoscopic solutions for clinicians and patients, allowing more risk categories to benefit from it. Benefit from endoscopic diagnosis and treatment. | Series A / Apr 07, 2025 | |
Hengyu Biotechnology
|
Hengyu Biotechnology is a CXO platform founded by a scientific research team that provides biosafety testing and related process validation. | $27.8M / Series B / Mar 11, 2024 | |
Weimu Medical
|
Weimu Medical is a high-end interventional medical device developer. | $14M / Series A / Dec 06, 2023 | |
Baiying Bio
|
Baiying Bio offers economic recombinant protein and antibody reagents and is a CRO vendor for life science researchers and biopharma companies. They provide services including HTP recombinant antibody and VHH production, bispecific antibody production, antibody humanization, VHH library generation, hybridoma sequencing, protein expression inmammalian cells, large-scale antibody production, and more. They delivered tens of thousands of recombinant antibodies to customers. | $72.6M / Series B / Aug 31, 2022 | |
Biointron
|
Biointron is committed to providing high-quality and economic recombinant protein/antibody reagents. The company was founded in 2012 and is headquartered in Shanghai, China. | $72.6M / Series B / Aug 31, 2022 | |
Porton Advanced Solutions
|
Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To meet the therapeutic product needs of our clients at the pre-clinical, clinical, and commercial stages, we offer end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services. | $80M / Series B / Aug 21, 2022 | |
|
Hengyu Biotechnology
|
Hengyu Biotechnology is a CXO platform founded by a scientific research team that provides biosafety testing and related process validation. | Series A / Jul 25, 2022 | |
| See all 21 investments → | |||
Co-Investors
Addor Capital
2 deals together
ALAN AMC
2 deals together
Gaorong Capital
2 deals together
Binfu Capital
2 deals together
CMG-SDIC Capital Management
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does CS Capital invest in?
CS Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 21 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CS Capital?
Public channels for CS Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CS Capital?
The team at CS Capital includes Min Lou (CEO & Co-founder) and Yinghui Wu (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
